APC

(redirected from Adenomatous polyposis coli)
Also found in: Dictionary, Thesaurus, Medical, Acronyms, Wikipedia.
Related to Adenomatous polyposis coli: Familial adenomatous polyposis

APC

(cell and molecular biology)
(electronics)

APC

On drawings, abbr. for “acoustical plaster ceiling.”

APC

APC

(1) (American Power Conversion Corporation, West Kingston, RI, www.apcc.com) The leading manufacturer of UPS systems and surge suppressors, founded in 1981 by Rodger Dowdell, Neil Rasmussen and Emanual Landsman, three electronic power engineers who had worked at MIT. Although created to develop solar electricity, the company introduced its first UPS system three years later as government funding for solar energy dissipated.

(2) (Application Performance Characterization) A graphics benchmark that tests actual application performance. See GPC.
References in periodicals archive ?
A review of the Familial Adenomatous Polyposis Coli products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
Coverage of the Familial Adenomatous Polyposis Coli pipeline on the basis of therapeutic class, route of administration and molecule type.
1, 1999, the company announced that it anticipated a delay in commercialization of exisulind for Adenomatous Polyposis Coli (APC) because a preliminary evaluation suggested that data produced in its recently concluded Phase III study did not provide the overall statistical results which the study was designed to provide.
Nasdaq:CLPA) today announced that it anticipates a delay in the filing of its NDA for its novel investigational drug, PREVATAC(tm) (exisulind) for Adenomatous Polyposis Coli (APC), which was initially planned for March of this year.
The company's lead investigational drug, PREVATAC(tm)(exisulind) is currently completing a Phase III study for the prevention of the formation of precancerous colon polyps in patients with adenomatous polyposis coli (APC)(also known as familial adenomatous polyposis, or FAP).
That drug is currently completing a Phase III trial as a treatment for precancerous colon polyps in patients with adenomatous polyposis coli (APC), and is additionally under study for the prevention of prostate and breast cancer recurrence and as a treatment for sporadic precancerous colon polyps and lung cancer.
Cell Pathways is currently completing a Phase III trial with its lead compound, PREVATAC(tm) (exisulind), for the treatment of precancerous lesions in patients with adenomatous polyposis coli (APC), and expects to complete a New Drug Application filing for this indication in the first half of 1999.